Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
- PMID: 17190952
- DOI: 10.1212/01.wnl.0000249308.66959.43
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
Abstract
In this multicenter study of 100 patients with cervical dystonia, we examined the immunogenicity of botulinum toxin type B (BTX-B) and correlated the clinical response with the presence of blocking antibodies (Abs) using a novel mouse protection assay. One-third of the patients who were negative for BTX-B Abs at baseline became positive for BTX-B Abs at last visit. Thus, the high antigenicity of BTX-B limits its long-term efficacy.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources